The discovery that androgens play an important role in the progression of prostate cancer (PCa) led to the development of androgen deprivation therapy (ADT) as a first line of treatment. However, paradoxical growth inhibition has been observed in a subset of PCa upon administration of supraphysiological levels of testosterone (SupraT), both experimentally and clinically.